FLI1 and Bloom syndrome: As the protein stability of Fli1 increases when Fli1 binds to DNA, and is protected from degradation, these in vivo data suggest that bosentan prevents the development of dermal fibrosis in BLM-treated mice by increasing the DNA binding of Fli1 in lesional dermal fibroblasts.